Non-pregnant and non-lactating; women of child-bearing potential must have a negative urine or serum pregnancy test prior to registration; peri-menopausal women must be amenorrheic >= 12 months prior to registration to be considered not of childbearing potential
Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
For women of childbearing potential only: a negative urine or serum pregnancy test done =< 7 days prior to pre-registration is required
Not pregnant and not nursing; for women of childbearing potential only, a negative pregnancy test done =< 7 days prior to registration is required
Not pregnant and not nursing; therefore, for women of childbearing potential only, a negative pregnancy test done =< 7 days prior to re-registration is required
Not pregnant and not nursing; for women of childbearing potential only, a negative pregnancy test done =< 7 days prior to registration is required
Not pregnant and not nursing; women of childbearing potential only, a negative pregnancy test done =< 7 days prior to registration is required
Pregnancy test done within 14 days prior randomization must be negative (for women of childbearing potential only); pregnancy testing should be performed according to institutional standards; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
Negative serum or urine pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
Negative serum pregnancy test within 14 days prior to registration for women of childbearing potential
Negative serum pregnancy test within 2 weeks prior to registration for women of childbearing potential
Not pregnant and not nursing; for women of childbearing potential only, a negative urine or serum pregnancy test done =< 8 days prior to registration is required
Not pregnant and not nursing; therefore, for women of childbearing potential only, a negative (if your test schedule specifically indicates a urine or serum pregnancy test, add that information at this point) pregnancy test done =< 28 days prior to registration is required
Women of childbearing potential must have a negative serum pregnancy test within 21 days prior to study entry
Not pregnant and not nursing; for women of childbearing potential only, a negative pregnancy test done =< 7 days prior to registration is required
Serum or urine pregnancy test must be negative in premenopausal women within 14 days of randomization, or in women with amenorrhea of less than 12 months at time of randomization.
Pregnant women, or women of childbearing potential without a negative pregnancy test within 14 days prior to randomization.
Negative serum pregnancy test if women of childbearing potential (WOCBP) (non-childbearing is defined as greater than one year postmenopausal or surgically sterilized)
Women of childbearing potential must have pregnancy excluded by appropriate testing before study entry
Women of childbearing potential must have a negative serum or urine pregnancy test within 96 hours prior to start of study drug.
Negative serum pregnancy test for women of childbearing potential
Pregnant or lactating women; a negative pregnancy test in women of childbearing potential must be documented within 7 days before the first dose of study medication
Negative pregnancy test for women of childbearing potential (< 51 years of age) as per institutional policy
Women of childbearing potential must have a negative serum or urine pregnancy test at screening
Negative pregnancy test performed =< 7 days prior to registration (women of childbearing potential only)
Negative serum pregnancy test in women of childbearing potential (WOCBP)
Negative pregnancy test within 2 weeks prior to treatment for women of childbearing potential
Negative pregnancy test at the Screening visit for women of childbearing potential and willingness to use adequate birth control
INCLUSION CRITERIA FOR SECOND-LINE THERAPY: Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of treatment and/or postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential
INCLUSION CRITERIA FOR THIRD-LINE THERAPY: Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of treatment and/or postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential
Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to study registration; post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test; the definition of adequate contraception will be based on the judgment of the investigator
A negative pregnancy test =< 7 days prior to treatment for premenopausal women and for women < 1 year after the onset of menopause
Negative serum pregnancy test within 7 days prior to study treatment in premenopausal women and women less than (<) 12 months after menopause
Women of childbearing potential (defined as women under the age of 55 with intact ovaries and uterus) must agree to use adequate contraception prior to study entry and for the duration of study participation; they must also have a negative urine pregnancy test within 7 days of starting treatment
Women of childbearing potential must have a negative pregnancy test
For women of childbearing potential (defined as women with menses within the past 2 years), a negative serum pregnancy test must be documented prior to registration; NOTE: in addition to screening, serum pregnancy test must be performed on females of childbearing potential within 72 hours before the start of investigational product; when possible, these tests can be one-in-the-same (if screening pregnancy test was performed within 72 hours of first ponatinib dose, no need to repeat)
Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to randomization and agree to use effective contraception
Women of childbearing potential must have negative pregnancy test within 24 hours of enrollment
Women of childbearing potential must have a negative serum pregnancy test less than or equal to 7 days prior to registration.
Negative serum pregnancy test for women of childbearing potential
Negative serum pregnancy test in women of childbearing potential
Women of childbearing potential must have a negative pregnancy test
Negative serum/urine pregnancy test (for women of childbearing potential)
Positive pregnancy test; Note: Pregnant women are excluded from this study; breastfeeding should be discontinued; negative serum pregnancy test will be required for women of childbearing potential
Pregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 7 days of study entry
Negative pregnancy test by urine or serum or waiver of pregnancy testing per local institutional policy within 30 days prior to randomization according to local standards for women of childbearing potential
Not pregnant and not nursing; for women of childbearing potential only, a negative serum pregnancy test done =< 7 days prior to registration is required
Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to registration
Women of childbearing potential must have a negative urine pregnancy test at the screening visit
Women of childbearing potential must have a negative serum pregnancy test
Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
Women of childbearing potential must have a negative qualitative serum pregnancy test =< 14 days prior to Step 1 registration
Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
Pregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 14 days of study entry
Women of childbearing potential must have a negative pregnancy test within 14 days of registration
Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug; post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test; the definition of adequate contraception will be based on the judgment of the investigator
Women of childbearing potential must indicate that there is not a possibility of being pregnant at the time of enrollment or have a negative serum pregnancy test prior to the initiation of radiation therapy
Negative serum pregnancy test within 7 days prior to study treatment in premenopausal women and women <= 2 years after menopause
Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
Women of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to the start of the study
Women of childbearing potential (WOCBP) must have negative urine pregnancy test within 7 days of day 1 (D1) of treatment
Women of childbearing potential must have a negative pregnancy test.
Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
Women must not be pregnant or breastfeeding; females of childbearing potential should have 2 negative pregnancy tests (sensitivity of at least 50 mIU/mL); the first test should be performed within 10-14 days, and the second test within 24 hours prior to prescribing lenalidomide
Pregnancy or lactation at the time of proposed study entry. Women of reproductive potential must agree to use an effective non-hormonal method of contraception during therapy such as an intrauterine device or condom with spermicide. (Note: Women of childbearing potential must have a negative serum pregnancy test within 3 weeks of study registration).
Women should not be lactating and, if of childbearing age, have a negative pregnancy test within two weeks of entry to the study
Negative pregnancy test (within 7 days of enrollment) in women of childbearing potential
Negative serum or urine pregnancy test for women within 72 hours of receiving the first dose of the study medication for women of childbearing potential.
Negative serum pregnancy test within 7 days prior to commencement of dosing in premenopausal women. Women of non-childbearing potential may be included without serum pregnancy test if they are either surgically sterile or have been postmenopausal for >= 1 year
Women of childbearing potential must have a negative pregnancy test within 72 hours prior to receiving the first dose of study medication
Negative pregnancy test done ? 7 days prior to registration, for women of childbearing potential only
Pregnant or nursing women. \r\n* NOTE: Women of reproductive potential must have a negative serum pregnancy test performed within 48 hours of starting conditioning chemotherapy
Women of childbearing potential who are not using an effective method of contraception are excluded. Women of childbearing potential must have a negative urine or serum pregnancy test within 24 hours prior to administration of SRS
Pregnant or lactating, or intending to become pregnant during the study\r\n* Women of childbearing potential must have a negative serum pregnancy test result within 21 days prior to initiation of study drug
Pregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 14 days of study entry
Women of childbearing potential must have a negative serum pregnancy test at screening and =< 72 hours prior to day 1 of study treatment
Negative serum pregnancy test within 7 days of commencement of treatment in women of childbearing potential
Patients who are pregnant or nursing; women of childbearing potential (WOCBP) will have to undergo a urine pregnancy test as part of screening
Women of childbearing potential must have a negative serum or urine pregnancy test within 10-14 days prior to enrollment
Women of childbearing potential must have a negative serum or urine pregnancy test within 48 hours prior to the start of nivolumab.
Pregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 14 days of study entry
Negative pregnancy test (women of childbearing potential)
Women of childbearing potential must have a negative urine pregnancy test within 7 days prior to initiation of treatment; women will be considered not of childbearing potential if they are surgically sterile (bilateral oophorectomy or hysterectomy) and/or post-menopausal (amenorrheic for at least 12 months)
Female participants who are pregnant or breastfeeding; women of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to randomization; all women of childbearing potential must be willing to comply with an acceptable birth control regimen to prevent pregnancy while receiving treatment and for 3 months after treatment is discontinued as determined by the Investigator; post-menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential; (note: a woman of childbearing potential is one who is biologically capable of becoming pregnant; this includes women who are using contraceptives or whose sexual partners are either sterile or using contraceptives)
Pregnant or nursing women; NOTE: Women of reproductive potential must have a negative serum pregnancy test performed within 48 hours of starting conditioning chemotherapy
Women of childbearing potential must have a negative serum or urine pregnancy test performed within 7 days prior to the start of study drug; post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test
Negative serum pregnancy test for persons of childbearing potential =< 7 days prior to registration
Women of childbearing potential must have a negative serum or urine pregnancy test.
Non pregnant and non-nursing women; women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment
Women of childbearing potential (WOCBP) must have a negative urine or serum pregnancy test for the patient to be eligible for trial enrolment
Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only; Note: patients must agree to adequate birth control during the study and for up to 6 months after discontinuation of study medication
Pregnancy, lactation, or breast-feeding; women of childbearing potential must have a negative urine pregnancy test at screening
Negative urine pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
Negative pregnancy test done =< 7 days prior to registration, for persons of childbearing potential only
Negative serum pregnancy test within 2 weeks of enrollment for women of childbearing potential, defined as those who have not been surgically sterilized or who have not been free of menses for at least 1 year
Negative serum pregnancy test within 2 weeks of lymphodepletion chemotherapy for women of childbearing potential, defined as those who have not been surgically sterilized or who have not been free of menses for at least 1 year
Women of childbearing potential must have a negative urine or serum pregnancy test at screening within 14 days prior to randomization
Pregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 14 days of study entry
Women of childbearing potential must have negative pregnancy test prior to initiating study treatment.
Women of childbearing potential must have a negative serum or urine pregnancy test within 1 day prior to administration of the first dose of chemotherapy
Women of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to the first dose of pembrolizumab
Negative serum pregnancy test within 14 days prior to registration for women of childbearing potential
If a female of childbearing potential, has a negative serum blood pregnancy test during screening and a negative urine pregnancy test within 3 days prior to receiving the first dose of study drug; if the screening serum test is done within 3 days prior to receiving the first dose of study drug, a urine test is not required; Note: Women of childbearing potential (WoCP) are any women between menarche and menopause who have not been permanently or surgically sterilized and are capable of procreation; permanent sterilization includes hysterectomy and/or bilateral oophorectomy and/or bilateral salpingectomy but excludes bilateral tubal occlusion; WoCP include non-women who have experienced menopause onset < 12 months prior to enrollment
Women of childbearing potential must have a negative serum pregnancy test within 28 days prior to registration; women of non-childbearing potential are defined as those who have no uterus, ligation of the fallopian tubes, are naturally postmenopausal for at least 12 consecutive months or have undergone surgical removal of the ovaries
Negative pregnancy test done =< 7 days prior to registration, for persons of childbearing potential only
Negative serum or urine pregnancy test at screening for women of childbearing potential
Women of childbearing potential must have a negative serum or urine pregnancy test at time of screening and confirmed within 3 days prior to treatment; women not of child-bearing potential will be defined as all women older than age 50 and anovulatory for 12 months
Negative serum pregnancy test within 7 days prior to cycle 1/day 1 for women of childbearing potential
Urine pregnancy test is negative for women of childbearing potential, within 14 days before study treatment
Pregnancy or lactating females; women of childbearing potential must have a negative serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to Step 2 registration
Negative pregnancy test and willingness to utilize contraception among women of childbearing potential
Negative serum pregnancy test at screening for women of childbearing potential
Women of childbearing potential (WOCBP) must have a negative serum pregnancy test (sensitivity =< 25IU HCG/L) within 4 weeks prior to registration and will be repeated within 72 hours prior to the start of study drug administration
For women of childbearing potential, a negative serum or urine pregnancy test with sensitivity less than 50 mIU/m within 72 hours before the start of study medication
Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
A negative urine pregnancy test is required within 1 week for all women of childbearing potential prior to enrolling on this trial
DONOR: Women of childbearing potential (WOCBP): Urine pregnancy testing performed within 7 days prior to stem cell mobilization
Sex and reproductive status; a) women of childbearing potential (WOCBP) who are pregnant or breastfeeding; b) women with a positive pregnancy test at enrollment or prior to administration of study medication
Women of childbearing potential must have a negative serum or urine pregnancy test within 3 days prior to treatment; women not of child-bearing potential will be defined as all women older than age 50 and anovulatory for 12 months
Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to cycle 1 day 1 and agree to use effective contraception, throughout the treatment period, and for 4 months after the last dose of study treatment
Women of childbearing potential must have a negative urine or blood pregnancy test within 14 days of study enrollment
Negative serum pregnancy test at screening for women of childbearing potential
Negative serum or urine pregnancy test within 2 weeks before registration for women of childbearing potential
Pregnant and/or breastfeeding; women of childbearing potential must have a negative urine pregnancy test within 7 days of study entry
Negative serum pregnancy test at screening for women of childbearing potential
Negative serum pregnancy test within =< 7 days prior to the first dose of study drug, for women of childbearing potential only
Women who are pregnant or breast-feeding, or intend to become pregnant during the study; women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug; post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test
Negative serum pregnancy test for women of childbearing potential =< 7 days prior to registration; Note: a second pregnancy test may be required =< 72 hours prior to receiving the first dose of study medication
Pregnant and/or breastfeeding; women of childbearing potential must have two negative pregnancy tests; the first test should be performed within 10-14 days of study entry, and the second test within 24 hours prior to prescribing pomalidomide
Pregnant or breast-feeding patients; women of childbearing potential (WOCBP) must have a serum pregnancy test performed a maximum of 7 days before the start of study treatment, and a negative result must be documented before the start of study treatment
Pregnancy or breastfeeding; a pregnancy test must be performed within 7 days prior to ibrutinib initiation in women of childbearing potential; pregnant women; breastfeeding must be discontinued because of unknown but potential risks in the nursing infant
Pregnant women, or women of childbearing potential without a negative pregnancy test (serum or urine) within 7 days prior to randomization, irrespective of the method of contraception used, are excluded from this study; breastfeeding must be discontinued prior to study entry
Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
All women of childbearing potential must have a negative urine or serum pregnancy test at screening.
Positive pregnancy test for women of childbearing age
Women of childbearing potential must have a negative serum or urine pregnancy test within 28 days prior to registration; women of non-childbearing potential are defined as those who have no uterus, ligation of the fallopian tubes, or permanent cessation of ovarian function due to ovarian failure or surgical removal of the ovaries; all others are considered women of child bearing potential
Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of treatment and/or postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential
Women of childbearing potential also may not be breast feeding and must have a negative serum or urine pregnancy test within 72 hours before the start of study treatment
Women of childbearing potential (WOCBP) must have a negative urine or serum pregnancy test for the patient to be eligible for trial enrollment
Negative urine or serum pregnancy test for women of childbearing potential
For women of childbearing age, negative pregnancy test within 14 days prior to registration
Pregnant or breast feeding women are excluded from participating in this study; WOCBP must have a negative serum pregnancy test within 7 days of the first administration of decitabine
Women of childbearing potential must have a negative pregnancy test within 7 days of starting treatment
A negative pregnancy test (only for women of childbearing potential [WOCBP])
Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment
Women of childbearing potential must have a negative urine or serum pregnancy test within 14 days of study entry
Women of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to the start of nivolumab
Pregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 14 days of study entry
Women of childbearing age must have a negative serum pregnancy test to meet eligibility per Duke policy
Women of childbearing potential must have a negative pregnancy test; women of childbearing potential are defined as all women except women who are postmenopausal or who have had a hysterectomy; postmenopausal will be defined as women over the age of 55 who have not had a menstrual period in at least one year; breastfeeding should be discontinued if the mother is treated with E7 TCR transduced peripheral blood lymphocyte (PBL); these potential risks may also apply to other agents used in this study
Not pregnant or breastfeeding; a negative pregnancy test is required within 14 days of registration for pre- or perimenopausal (i.e., last menstrual period within one year of registration) women
A negative serum pregnancy test at screening for women of childbearing potential (WOCBP)
Persons of reproductive potential must agree to an adequate method of contraception throughout treatment and for at least 4 weeks after study drug is stopped\r\n* Women of childbearing potential must have a negative serum or urine pregnancy test within 8 days prior to start of study drug administration
PHASE I: Negative urine pregnancy test =< 3 days prior to course 1 day 1 (C1D1) (women of childbearing potential only)
Women of childbearing potential must have a negative serum or urine pregnancy test within 3 days prior to treatment
Women of childbearing potential must have a negative serum pregnancy test during the Screening Period and within 48 hours of the first dose of ARQ 751. \Women of childbearing potential\ is defined as sexually mature women who have not undergone a hysterectomy or who have not been naturally postmenopausal for at least 12 consecutive months prior to the first dose of ARQ 751.
Pregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 3 days of signing consent
Women who are pregnant, which includes women with a positive pregnancy test at enrollment or prior to the administration of study medication, or breastfeeding are not allowed on study
Women of childbearing potential must have a negative qualitative serum pregnancy test =< 2 weeks prior to study entry
Women of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to start of IRX5183
Pregnant and/or breastfeeding; women of childbearing potential must have a negative serum or urine pregnancy test within 7 days of study entry
Negative urine or serum pregnancy test done =< 21 days prior to computed tomography (CT) simulation, for women of childbearing potential only
Negative serum pregnancy test within 7 days prior to commencement of dosing in premenopausal women; women of non-childbearing potential may be included without serum pregnancy test if they are either surgically sterile or have been postmenopausal for >=1 year
Pregnancy restrictions - Women of childbearing potential must have a negative B-HCG documented within 7 days prior to registration
Women who are pregnant or lactating. Women of childbearing potential must have a negative serum or urine pregnancy test performed within 7 days prior to start of treatment. Women of childbearing potential or men with partners of childbearing potential must use effective birth control measures during treatment.
Pregnant and breastfeeding women will be excluded; women of childbearing potential must have a negative pregnancy test within 14 days of initiation of treatment
Negative pregnancy test for women of childbearing potential; subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year
INCLUSION CRITERIA FOR TNBC: Negative pregnancy test for women of childbearing potential; subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year
Negative serum pregnancy test within 48 hours before starting study treatment in women with childbearing potential
Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
Women of pregnancy potential must practice an effective method of birth control during the course of the study, in a manner such that risk of failure is minimized; prior to study enrollment, women of childbearing potential (WOCBP) must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an unintentional pregnancy; postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential; women must continue birth control for the duration of the trial and at least 3 months after the last dose of study drug; pregnant or breast-feeding women are excluded; all WOCBP must have a negative pregnancy test prior to first receiving investigational product; if the pregnancy test is positive, the patient must not receive investigational product and must not be enrolled in the study
A negative serum or urine pregnancy test must be done within 72 hours before the first dose of the study medication for women of childbearing potential as per institutional guidelines; post-menopausal women (defines as no menses for at least 1 year) and surgically sterilized women are not required to undergo pregnancy test
Pregnant and/or breastfeeding; women of childbearing potential must have a negative serum or urine pregnancy test within 7 days of study entry
Negative serum or urine pregnancy test for women with reproductive potential
Pregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 14 days of study entry
Negative serum pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
Women of childbearing potential must have a negative serum or urine pregnancy test within 14 days of treatment.
Negative urine or blood pregnancy test for women of childbearing potential
Women of childbearing potential (defined as having a menstrual cycle within the past 12 months and not having had a surgical procedure to accomplish sterilization) must have a negative serum pregnancy test within seven days of screening and within 24 hours prior to the start of each nivolumab dose
Negative pregnancy test within 7 days prior to commencement of dosing in premenopausal women, women of non childbearing potential may be included without serum pregnancy test if they are either surgically sterile or have been postmenopausal for >= 1 year
Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
Pregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 72 hours of study entry
Pregnant and/or breastfeeding; women of childbearing potential must have a negative serum pregnancy test within 14 days of study entry
Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug; post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test
Pregnant or breast-feeding patients; women of childbearing potential must have a pregnancy test performed a maximum of 7 days before start of treatment, and a negative result must be documented before start of treatment
Non-pregnant and non-nursing women of childbearing potential must have a negative serum or urine pregnancy test within 3 days of crenolanib commencement (\Women of childbearing potential\ is defined as a sexually active mature woman who has not undergone a hysterectomy or who has had menses at any time in the preceding 24 consecutive months).
Women of childbearing potential must have a negative blood pregnancy test at the screening visit
Pregnant or nursing; women of childbearing potential must have a negative pregnancy test within 14 days of study entry
Pregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 7 days of study entry
Negative serum pregnancy test within 7 days prior to commencement of dosing in women of childbearing potential
Negative serum or urine pregnancy test for women within 72 hours of receiving the first dose of the study medication for women of childbearing potential
Women of childbearing potential (WOCBP) must have negative pregnancy test within 72 hours prior to day (D)1 of treatment
Negative serum or urine pregnancy test for women within 72 hours of receiving the first dose of the study medication for women of childbearing potential
For women of childbearing potential only: Negative pregnancy test =< 10-14 days prior to registration; NOTE: the patient must have an additional negative pregnancy test =< 24 hours prior to receiving the initial prescription of lenalidomide, per requirements of the REVLIMID Risk Evaluation and Mitigation Strategies (REMS) program
Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of treatment.
Female patients who are pregnant or breast-feeding (confirmation that the patient is not pregnant must be by a negative pregnancy test result obtained during screening; pregnancy testing is required of women of childbearing potential but not required for post-menopausal or surgically, sterilized women)
Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of study entry.
Negative pregnancy test for women of childbearing potential within 14 days prior to registration
Non-pregnant and non-nursing women of childbearing potential must have a negative serum or urine pregnancy test (\Women of childbearing potential\ is defined as a sexually active mature woman who has not undergone a hysterectomy or who has had menses at any time in the preceding 24 consecutive months)
Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment
Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
Negative serum pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
Positive pregnancy test for women of childbearing age
Women of childbearing potential who have a positive result on screening urine pregnancy test
Negative serum pregnancy test (women of childbearing potential only)
Negative serum pregnancy test for women of childbearing potential
Negative serum pregnancy test for women of childbearing potential
Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days; women of childbearing potential and men must agree to use contraception at study entry and for the duration of active study treatment
A negative urine pregnancy test is required within 1 week for all women of childbearing potential prior to enrolling on this trial
Are pregnant or breast-feeding. In women of childbearing potential, a negative serum pregnancy test is required prior to study treatment.
Negative pregnancy test in women of childbearing age
A negative pregnancy test within 7 days prior to registration for women of childbearing potential; in addition, male and female participants must commit to adequate contraception while on study
Women of reproductive potential must have negative urine pregnancy test
Negative serum pregnancy test within 72 hours prior to the first study dose in all women of childbearing potential
Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment
For women of childbearing age, a negative pregnancy test performed within 14 days of surgery
Negative serum pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
Women of childbearing potential must have a negative serum or urine pregnancy test performed within 7 days prior to FDG-PET-MRI
A negative urine pregnancy test is required within 1 week for all women of childbearing potential prior to enrolling on this trial
Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to study entry
Women of childbearing potential must have a negative serum or urine pregnancy test within 2 weeks prior to initiation of therapy
A negative urine pregnancy test is required within 1 week for all women of childbearing potential prior to enrolling on this trial
Women of childbearing potential must have a pregnancy test at screening
Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of treatment and/or postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential
Women who are pre-menopausal must have a negative serum pregnancy test; subjects must agree to use appropriate contraception until 4 weeks after the completion of chemotherapy
Negative serum pregnancy test in women of childbearing potential
Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
Negative pregnancy test performed =< 7 days prior to registration for women of childbearing potential only
Negative pregnancy test (urine or serum), within 7 day prior to day 1 of FOLFIRI in women of childbearing potential
For women of childbearing potential, negative urine or serum pregnancy test within 6 weeks prior to study entry
Women of childbearing potential who are not using an effective method of contraception are excluded; women of childbearing potential must have a negative urine or serum pregnancy test within 24 hours prior to administration of SRS
Women who are able to conceive and unwilling to practice and effective method of birth control; women of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to treatment
Pregnant women will not be eligible; women of childbearing potential must have a negative pregnancy test before starting therapy
Negative serum or urine pregnancy test within 72 hours prior to registration for women of childbearing potential
Negative serum or urine pregnancy test done =< 7 days prior to registration, for persons of childbearing potential only
Negative serum pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
Women of child-bearing potential must have a negative serum pregnancy test during Screening and a negative urine pregnancy test within 24 hours prior to first dose of study treatment. Non-childbearing is defined as greater than one year postmenopausal or surgically sterilized.
Negative serum pregnancy test result within 14 days prior to study drug among women of childbearing potential
Women of childbearing potential must have a negative serum beta-HCG pregnancy test documented within 3 days prior to study initiation.
Negative serum pregnancy test within 48 hours before starting study treatment in women with childbearing potential
Women of childbearing potential must have a negative pregnancy test within 7 days of starting treatment
Childbearing age women with negative pregnancy test
Women of childbearing potential who have a negative pregnancy test within 7 days of the first dose of sorafenib in this long term extension program.
Pregnant women or women of childbearing potential and not using methods to avoid pregnancy; a negative pregnancy test (urine or serum) must be documented at baseline for women of childbearing potential; no breast-feeding while on study.
Women of childbearing potential who have negative pregnancy test results
Negative pregnancy test in women of childbearing potential
6. Women must not be pregnant or breastfeeding. Women of childbearing potential must have a negative serum or urine pregnancy test within 14 days prior to start of study drug administration.
Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 24 hours of study entry
Negative serum pregnancy test done ? 7 days prior to registration, for persons of childbearing potential only
Female patients who are pregnant, breast feeding, or of childbearing potential without a negative pregnancy test prior to baseline. Women of childbearing potential must have a negative serum pregnancy test as a part of eligibility, within 28 days of registration.
Negative pregnancy test done at screening and ? 3 days (72 hours) prior to registration, for women of childbearing potential
Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of study entry and again within 24 hours prior to first treatment.
Negative pregnancy test performed =< 7 days prior to registration (women of childbearing potential only)
Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 7 days of first dose of vaccine.
Women of childbearing potential must have a negative serum or urine pregnancy test within 28 days prior to initiation of treatment AND confirmed prior to initiation of treatment on day 1
Negative pregnancy test done =< 7 days prior to registration, for persons of childbearing potential only
Pregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 14 days of study entry
Women who are pregnant and/or breastfeeding. Women of childbearing potential must have a negative serum or urine pregnancy test within 24 hours prior to the start of nivolumab.
Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to randomization and must agree to use effective contraception throughout the treatment period and for 4 months after the last dose of study treatment
Women of childbearing potential must have a negative pregnancy test within 30 days of registration
Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
A negative urine pregnancy test is required within 1 week for all women of childbearing potential prior to enrolling on this trial
Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug; post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test; the definition of adequate contraception will be based on the judgement of the investigator
Pregnant or lactating women; pregnant women are excluded from this study; women of childbearing potential must have a negative pregnancy test per standard of care prior to the surgery for tumor removal; a second pregnancy test must be performed 7 days prior to the first vaccination and must be negative; breastfeeding should be discontinued if the mother is treated on study
Negative serum pregnancy test =< 7 days prior to registration for women of childbearing potential\r\n* NOTE: women will be considered not of childbearing potential if they are surgically sterile (bilateral oophorectomy or hysterectomy) and/or post-menopausal (amenorrheic for at least 12 months)
Not pregnant and not nursing; for women of childbearing potential only, a negative pregnancy test done =< 7 days prior to registration is required
Negative urine or serum pregnancy test for women of childbearing potential within 7 days prior to study entry
Negative serum pregnancy test done =< 14 days prior to randomization, for women of childbearing potential only
For women of childbearing potential, a negative serum pregnancy test within 14 days of registration
Women who are not postmenopausal or surgically sterile must have a negative serum pregnancy test result within 28 days prior to initiation of study drug
Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
Negative urine or serum pregnancy test within 14 days prior to registration for women of childbearing potential
ARM A: Negative serum pregnancy test =< 7 days prior to registration for women of childbearing potential only
ARM B: Negative serum pregnancy test =< 7 days prior to registration for women of childbearing potential only
Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
Women of childbearing potential must have a negative urine pregnancy test within 7 days prior to initiation of treatment, women will be considered not of childbearing potential if they are surgically sterile (bilateral oophorectomy or hysterectomy) and/or post-menopausal (amenorrheic for at least 12 months)
Negative pregnancy test (either urine or serum) within 14 days prior to randomization for all women of childbearing potential (above)
Negative serum pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
For women of childbearing potential only: negative urine or serum pregnancy test done =< 7 days prior to registration
Negative serum pregnancy test within 7 days of treatment initiation with ibrutinib in women of childbearing potential (WOCBP)
Negative (serum or urine) pregnancy test done =< 7 days prior to registration, for women of childbearing potential only; NOTE: a second pregnancy test must be performed within 24 hours prior to the start of lenalidomide; the subject may not receive lenalidomide until the study doctor has verified that the results of these pregnancy tests are negative
Participant is neither pregnant nor nursing:\r\n* Women of childbearing potential (WOCBP) must have a negative pregnancy test (minimum sensitivity 25 IU/L or equivalent of HCG) within 7 days prior to start of study medication; it is the investigatorsâ€™ responsibility to repeat the pregnancy test should start of treatment be delayed
Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to registration or randomization
Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
Pregnant women are excluded from this study; women of childbearing potential must have a negative pregnancy test
Negative serum pregnancy test done =< 7 days prior to registration (for women of childbearing potential only)
Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
Women of childbearing potential must have a negative serum or urine pregnancy test within 14 days of the administration of the first study treatment; women must not be lactating
Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug; post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test
Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of treatment and/or postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential
Negative serum pregnancy test within 72 hours before starting study treatment in women with childbearing potential
Women of childbearing potential must have a negative pregnancy test performed within 7 days prior to the start of study drug
Negative serum pregnancy test within 14 days prior to registration for women of childbearing potential
For women of childbearing potential, a serum pregnancy test within 72 hours prior to registration
Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 7 days prior to start of study treatment
Women of childbearing potential must have a negative serum pregnancy test within 7 days of the first dose of study treatment
Women of childbearing potential (defined as having a menstrual cycle within the past 12 months and not having had a surgical procedure to accomplish sterilization) must have a negative serum pregnancy test within seven days of screening
Women of childbearing potential (defined as having a menstrual cycle within the past 12 months and not having had a surgical procedure to accomplish sterilization) must have a negative serum pregnancy test within seven days of starting the vemurafenib
-Pregnant or lactating women.  Women of childbearing potential must have a negative\n             pregnancy test.  Pregnancy testing is not required for post-menopausal or surgically\n             sterilized women.
Women of childbearing potential only: negative serum pregnancy test done =< 14 days prior to registration
Negative serum or urine pregnancy test within 3 days prior to registration for women of childbearing potential
Negative serum pregnancy test within 48 hours before starting study treatment in women with childbearing potential
For women of childbearing potential, a negative serum or urine pregnancy test
For women of childbearing potential, a negative serum pregnancy test within 14 days prior to step 2 registration
For women of childbearing potential, a negative serum pregnancy test within 2 weeks of registration
Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug; post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test
Women of childbearing potential must have a negative serum pregnancy test performed within 14 days prior to enrollment; women of childbearing potential and men must agree to use adequate contraception prior to enrollment and for the duration of study participation
Patients of childbearing potential must have a negative pregnancy test prior to the study entry and be practicing an effective form of contraception; pregnant women are excluded from this study
Negative blood pregnancy test at Screening for women of childbearing potential
Negative serum pregnancy test in women of childbearing potential within 2 weeks of study
Premenopausal women must have a negative serum pregnancy test, including women who have had a tubal ligation and for women less than 12 months after the onset of menopause
Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to randomization, and must not be breastfeeding and must agree to use contraceptive for duration of study.
Women of childbearing potential must have a negative pregnancy test
Negative blood pregnancy test at the screening visit for women of childbearing potential
Negative serum pregnancy test for women of childbearing potential within 14 days of study registration
Negative serum pregnancy test within 2 weeks prior to registration for women of childbearing potential
Negative serum pregnancy test within 7 days of enrollment for pre-menopausal women and for women less than 12 months after the onset of menopause
Women of childbearing potential (i.e., menstruating women) must have a negative urine pregnancy test (positive urine tests are to be confirmed by serum test)
Negative serum pregnancy test within three days prior to registration for women of childbearing potential
Women of childbearing potential (WOCBP) with negative serum or urine pregnancy test within 7 days of day 1 (D1) of treatment
Pregnant and/or breastfeeding; women of childbearing potential must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10-14 days prior to and again within 24 hours of starting lenalidomide
Women must be determined to be not of childbearing potential (surgically sterile, or postmenopausal defined as amenorrheic for at least 12 months) by the Investigator OR they must have a negative serum pregnancy test prior to randomization.
Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug; post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test
Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of treatment. Female subject considered not of childbearing potential must be documented as being surgically sterile or post-menopausal for at least 1 year. Women of childbearing potential and men must agree to use adequate contraception.
Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment
Women of childbearing potential must have a negative pregnancy test prior to registration.
Pregnant or breastfeeding, or intending to become pregnant during the study; women of childbearing potential must have a negative serum pregnancy test result within 14 days prior to initiation of study treatment
Women of reproductive potential must have a negative serum pregnancy test obtained within 3 days before the start of anetumab ravtansine
Pregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 7 days of first dose of vaccine
Negative pregnancy test and willingness to utilize contraception among women of childbearing potential
Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug. Post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test. The definition of adequate contraception will be based on the judgment of the investigator.
Women of childbearing age with a negative pregnancy test documented prior to enrollment
Pregnancy or lactating females; women of childbearing potential must have a negative serum pregnancy test within 7 days prior to registration
Patients with a negative pregnancy test (urine or serum) must be documented within 28 days of starting treatment for women of childbearing potential (WOCBP)
Women of childbearing age with a negative pregnancy serum test documented prior to enrollment
A urine pregnancy test (within 7 days of enrollment date) is required for women with childbearing potential
Women of childbearing potential must have a negative pregnancy test within 14 days prior to registration for protocol therapy.
Women of reproductive potential must not be pregnant or breastfeeding and have a negative urine or serum pregnancy test obtained within 7 days prior to the first dose of study treatment.
Negative serum pregnancy test done =< 7 days prior to registration for women of childbearing potential only
Negative pregnancy test for women of childbearing potential (< 51 years of age) as per institutional policy
Postmenopausal or evidence of non-childbearing status for women of childbearing potential as confirmed by a negative urine or serum pregnancy test within 7 days prior to start of IPs
Pregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 28 days of study entry
Negative pregnancy test done =< 7 days prior to randomization, for women of childbearing potential only
Pregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 14 days of study entry
Women of childbearing potential must have a negative serum pregnancy test performed within 2 weeks prior to the start of study drug; post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test
Pregnant and/or breastfeeding; women of childbearing potential must have a negative serum or urine pregnancy test within 14 days of study entry
Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
Women of childbearing potential must have a negative serum pregnancy test within 7 days of the administration of the first study treatment; women must not be lactating; both men and women of childbearing potential must be advised of the importance of using effective birth control measures during the course of the study
Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to receiving study agents
Negative urine or serum pregnancy test done =< 7 days prior to registration/randomization, for women of childbearing potential only\r\n* NOTE: in the rare case that a woman enrolling on study is of childbearing potential, a pregnancy test is required prior to enrollment on study
Negative serum or urine pregnancy test in women with childbearing potential (WOCBP) defined as not post-menopausal for 12 months or no previous surgical sterilization, within one week prior to initiation of treatment; WOCBP must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 12 weeks after the last dose of study drug to minimize the risk of pregnancy
Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug; post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test
Women of childbearing potential must have a negative serum pregnancy test within the 14-day period prior to randomization. (Where demanded by local regulations, this test may be required within 72 hours of randomization.)
Negative serum pregnancy test done =< 7 days prior to randomization, for women of childbearing potential only; note: post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test; the definition of adequate contraception will be based on the judgment of the investigator
Women who are pregnant or breast-feeding; women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug; post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test
For women of childbearing potential, a negative serum pregnancy test =< 7 days prior to registration
Negative serum or urine pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
Negative serum pregnancy test within 72 hours before starting study treatment in women with childbearing potential
Women of childbearing potential must have a negative pregnancy test
Negative pregnancy test (women of childbearing potential)
Negative serum or urine pregnancy test within 2 weeks prior to registration for women of childbearing potential
Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of study drug administration
Negative pregnancy test within 7 days prior to starting the study premenopausal women; women of non-childbearing potential may be included without pregnancy test if they are either surgically sterile or have been postmenopausal for >= 1 year
Negative serum pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug; post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test
Women of childbearing potential must have a negative serum pregnancy test performed within 2 weeks prior to the start of study drug; post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test
Negative pregnancy test (women of childbearing potential only)
Women of childbearing potential must have negative serum pregnancy test performed within 7-days prior to registration
Negative pregnancy test for women of childbearing potential
Women of childbearing potential (WOCBP) must have negative pregnancy test within 7 days prior to day 1 (D1) of treatment
Women of childbearing potential must have a negative serum or urine pregnancy test at Screening
Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
Women of childbearing potential must have a negative pregnancy test within 30 days prior to study registration. Women should be counseled regarding acceptable birth control methods to utilize from the time of screening to start of treatment. If prior to treatment after discussion with the subject it is felt by the treating physician there is a possibility the subject is pregnant a pregnancy test should be repeated. Women of childbearing potential must have a negative pregnancy test within 30 days prior to study registration.
Women must not be pregnant or lactating; women of reproductive-potential must have negative serum or urine pregnancy test within 7 days prior to study enrollment and agree to use an effective method to avoid pregnancy during and for 30 days following last cessation drug dose
Negative serum pregnancy test within 14 days prior to registration for women of childbearing potential
Negative serum pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
Women of childbearing potential must have a negative serum pregnancy test =< 7 days prior to registration
Pregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 14 days of initiation of treatment
Women of childbearing potential must have a negative pregnancy test within 14 days of registration
Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug; post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test
A positive serum pregnancy test within 14 days prior to treatment in women of childbearing potential
Females must be surgically or biologically sterile or postmenopausal (amenorrheic for at least 12 months) or if of childbearing potential, must have a negative serum pregnancy test within 14 days before the start of the treatment; women of childbearing potential may have a urine pregnancy test, instead of a serum pregnancy test; if either the serum or urine pregnancy test is equivocally negative the patient will be eligible for the protocol; women of childbearing potential must agree to use an adequate method of contraception during the study until 30 days after the last treatment; males must be surgically or biologically sterile or agree to use an adequate method of contraception during the study until 30 days after the last treatment
Pregnant or breastfeeding patients; women of childbearing potential must have a documented negative pregnancy test a maximum of 7 days before start of treatment
Women of childbearing potential must have a negative serum or urine pregnancy test at screening
Premenopausal patients must have a negative serum or urine pregnancy test, including women who have had a tubal ligation and for women less than 12 months after the onset of menopause
Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug; post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test
Negative pregnancy test performed =< 7 days prior to registration, for women of childbearing potential only
Women of childbearing potential must have a negative serum or urine pregnancy test performed within 7 days prior to the start of study drug. Post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test.
Women of childbearing potential must have a negative pregnancy test within 7 days prior to study treatment
Pregnant or lactating women; women of childbearing potential with either a positive or no pregnancy test (serum or urine) at baseline; (postmenopausal woman must have been amenorrheic for at least 12 months to be considered of non-childbearing potential)
Negative serum pregnancy test within 72 hours before starting study treatment in women with childbearing potential
Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
Negative serum or urine pregnancy test; the pregnancy test result must be obtained prior to the first administration of AUY922 (=< 14 days prior to dosing) in all pre-menopausal women and women < 2 years after the onset of menopause
Women of childbearing potential must have a negative serum pregnancy test during Screening Period and within 48 hours of the first dose of ARQ 087.
Women of childbearing potential only: negative pregnancy test done =< 7 days prior to registration
Women of childbearing potential must have a negative serum/urine pregnancy test
Women of childbearing potential (WOCBP) must have a negative pregnancy test within 7 days of receiving study medication
Pregnant or lactating women; women of childbearing potential must have a negative pregnancy test at screening; women of child bearing potential must undergo pregnancy testing prior to each dose if the previous pregnancy test was greater than 14 days prior and a pregnancy test at 6 months after the last dose
Negative serum pregnancy test within 7 days of commencement of treatment in premenopausal women
Women of childbearing potential must have a negative pregnancy test within 7 days of starting treatment
Pregnant or breastfeeding; a negative pregnancy test is required within 14 days of randomization for all women of childbearing potential
Pregnant or lactating women; women of childbearing potential must have a negative pregnancy test at screening
Pregnancy or breast feeding - women of childbearing potential must have a negative pregnancy test within 28 days of study enrollment
Women of childbearing potential must have negative blood or urine pregnancy test at screening
Women of childbearing potential must have a negative pregnancy test prior to the first dose of study treatment.
Women of childbearing potential with negative serum pregnancy test prior to randomisation
Pregnant or lactating women; women of childbearing potential with either a positive or no pregnancy test (serum or urine) at baseline; (postmenopausal woman must have been amenorrheic for at least 12 months to be considered of non-childbearing potential)
Pregnant or lactating women; women of childbearing potential must have a negative pregnancy test at screening
Negative pregnancy test done =< 7 days prior to randomization, for women of childbearing potential only
Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of treatment and/or postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential
Pregnant or lactating women; women of childbearing potential with either a positive or no pregnancy test (serum or urine) at baseline; (postmenopausal woman must have been amenorrheic for at least 12 months to be considered of non-childbearing potential)
Women of childbearing potential must have a negative beta-HCG pregnancy test documented within 2 weeks prior to registration.
Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
Women of childbearing potential must have a negative, qualitative serum pregnancy test =< 2 weeks prior to study entry
Negative serum pregnancy test in women of childbearing potential
Women of childbearing potential must have a negative serum pregnancy test performed within 14 days prior to the start of pazopanib treatment and both men and women must be willing to use adequate contraception
Negative serum pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to treatment
Pregnant or breastfeeding patients; women of childbearing potential must have a pregnancy test performed a maximum of 7 days before start of FOLFIRI treatment, and a negative result must be documented before start of treatment
Women of childbearing potential must have a negative serum pregnancy test within 7 days of the administration of the first study treatment; women must not be lactating; both men and women of childbearing potential must be advised of the importance of using effective birth control measures during the course of the study
Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
Women of childbearing potential must have a negative serum pregnancy test at the time of transition to this study and before the first dose of study treatment
Negative urine or serum pregnancy test in women with childbearing potential (defined as not post-menopausal for 12 months or no previous surgical sterilization), within one week prior to initiation of treatment
Women of childbearing potential must have a negative pregnancy test performed within 14 days of the start of study drug. Both men and women enrolled in this study must agree to use adequate birth control measures while on study
Women of childbearing age must have a negative serum or urine pregnancy test prior to the initiation of study drug.
Women of childbearing potential must have a negative serum or urine pregnancy test upon study entry
Women of childbearing potential need to have a negative serum pregnancy test at the time of therapy
Serum or urine pregnancy test (for women of childbearing potential) negative =< 7 days of starting treatment
Postmenopausal or evidence of non-childbearing status for women of childbearing potential: negative urine or serum pregnancy test within 28 days of study treatment and confirmed prior to treatment on Day 1;
of childbearing potential (i.e., women with functional ovaries and no documented impairment of oviductal or uterine function that would cause sterility). This category includes women with oligomenorrhea [even severe], women who are perimenopausal or have just begun to menstruate. These women must have a negative serum pregnancy test at screening, and agree to one of the following:
Negative serum pregnancy test in women of childbearing potential;
Negative pregnancy test for women of childbearing potential
Women of childbearing potential must have a negative pregnancy test performed within 2 weeks prior to the start of treatment
Women of childbearing age must have a negative serum pregnancy test, and adequate contraception method(s) must be documented
Women of childbearing potential must have a negative serum pregnancy test and agree to use a medically accepted form of contraception from the time of initial screening through completion of the study
Negative serum pregnancy test within <30 days of surgery in pre-menopausal women and women < 2 years after the onset of menopause
Women of childbearing potential have a negative pregnancy test
Women of childbearing potential (not surgically sterilized or at least 2 years postmenopausal) must have a negative serum or urine pregnancy test performed within 7 days prior to the start of treatment
Pregnancy or nursing mothers; women of childbearing potential must have a negative pregnancy test and must agree to use adequate contraception prior to study entry and for the duration of study participation
Negative serum pregnancy test done =< 7 days prior to registration for women of childbearing potential only
Negative pregnancy test in women of childbearing potential (premenopausal or less than 12 months of amenorrhea post-menopause, and who have not undergone surgical sterilization), no more than 7 days before the first dose of study treatment
Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug. Post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test.
For women of childbearing potential, negative serum pregnancy test;
Negative urine or serum pregnancy test =< 14 days prior to registration for women of childbearing potential
Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of treatment and/or postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential
For women of childbearing potential, a negative serum or urine pregnancy test with sensitivity less than 50 mIU/m within 72 hours before the start of study medication
Women of childbearing potential (WOCBP) must have negative pregnancy test within 7 days prior to day 1 (D1) of treatment
Pregnant or breastfeeding; a negative blood-pregnancy test is required for women of childbearing potential (WOCBP) within 14 days prior to her computed tomography (CT) stimulation for treatment planning
Women of childbearing potential must have a negative serum pregnancy
Not pregnant and not nursing; for women of childbearing potential only, a negative serum pregnancy test pregnancy test done =< 7 days prior to pre-registration is required
Negative serum test for pregnancy in premenopausal women
Women of childbearing potential must have a negative serum or urine pregnancy test performed ? 7 days prior to start of treatment. Women of childbearing potential or men with partners of childbearing potential must use effective birth control measures during treatment and during the 3 months following completion of study treatment.
Negative urine pregnancy test within 7 days prior to commencement of dosing in premenopausal women; women of non-childbearing potential may be included without urine pregnancy test if they are either surgically sterile or have been postmenopausal for >= 1 year
Women of childbearing potential must have a negative serum pregnancy test prior to the study entry and be practicing an effective method of birth control during the course of the study, in a manner such that risk of failure is minimized; prior to study enrollment, women of childbearing potential must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an intentional pregnancy
Women of childbearing potential must have a negative pregnancy test performed within 7 days prior to the start of treatment
Negative serum or urine pregnancy test within 7 days prior to study treatment in premenopausal women and women </= 2 years after menopause (menopause is defined as amenorrhea for >/= 2 years)
Negative serum pregnancy test within 72 hours before starting study treatment in women with childbearing potential
For women of childbearing potential, a negative serum pregnancy test completed prior to any radiation therapy
Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug; post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test
Positive pregnancy test in women of childbearing potential
Women of reproductive potential must have negative urine pregnancy test
Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug; post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test
Women of childbearing potential must have a pregnancy test at screening
Negative pregnancy test for women of childbearing potential within 7 days of starting study treatment
Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug; post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test
Pregnancy or breastfeeding; a pregnancy test must be performed within 7 days prior to ibrutinib initiation in women of childbearing potential; pregnant women are excluded; breastfeeding must be discontinued
Negative pregnancy test done =< 14 days prior to registration, for women of childbearing potential only
Pregnant or breast-feeding women; women of childbearing potential must have a negative urine or serum pregnancy test within 14 days of start of treatment
Negative pregnancy test for women of childbearing potential
Women of childbearing potential must have a negative pregnancy test performed within 48 hours prior to the start of the study drug
Negative serum pregnancy test within 14 days prior to registration for women of childbearing potential
Negative serum pregnancy test =< 7 days prior to pre-registration for women of childbearing potential
For women of childbearing potential (WOCBP), a negative serum pregnancy test result at Screening.
Negative urine pregnancy test for women of childbearing potential
Adequate bone marrow function Women of childbearing potential must have a negative serum beta-HCG pregnancy test documented within 14 days prior to study initiation.
Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment
Pregnant or lactating women are not eligible; women of childbearing potential must have a negative serum or urine pregnancy test completed within 7 days of study treatment; women or men of childbearing potential not using a reliable and appropriate contraceptive method are not eligible; (postmenopausal woman must have been amenorrheic for at least 12 months to be considered of non-childbearing potential)
Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to randomization and agree to practice a medically acceptable contraceptive regimen from study treatment initiation until at least 30 days after the last administration of pralatrexate.
Pregnant or lactating women; women of childbearing potential must have a negative pregnancy test at screening
Negative pregnancy test within 2 weeks prior to registration for women of childbearing potential
Negative serum pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
For women of childbearing potential, have a negative pregnancy test (serum or urine) on Day 1 prior to initiating study treatment.
Serum or urine pregnancy test negative within 2 weeks for women of childbearing potential
Women who are pregnant or breast feeding or women of childbearing potential (WOCBP) not using an effective method of birth control; women of childbearing potential must have a negative serum pregnancy test within 24hrs prior to receiving the first dose of study medication
Women of childbearing potential must have a negative pregnancy test (urine or serum) performed within 7 days prior to the start of study drug.
Negative serum pregnancy test for female subjects with reproductive potential =< 7 days prior to registration, for women of childbearing potential only
Women able to conceive and unwilling to practice an effective method of birth control from screening until 90 days after discontinuing study treatment (women of childbearing potential must have a negative serum pregnancy test within 7 days prior to first dose of PQR309).
Pregnant or lactating women; female subjects of childbearing potential must indicate that there is not a possibility of being pregnant at the time of enrollment or have a negative pregnancy test prior to initiation of treatment; (postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential)
Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of treatment and/or postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential
Patients who are pregnant or nursing; women of childbearing potential (WOCBP) will have to undergo a urine pregnancy test as part of screening
Women must have a negative serum pregnancy test
Negative serum pregnancy test for pre-menopausal women and women within 12 months from the onset of menopause
Negative pregnancy test (urine dipstick or serum) for women of childbearing potential within 2 weeks prior to registration
Negative serum or urine pregnancy test must be obtained within 7 days before the first dose of study drug in women of childbearing potential. Negative results must be available before study drug administration
Women of childbearing potential must have a serum pregnancy test performed within 28 days prior to the first day of study drug dosing.
Women of childbearing age must have a negative urine pregnancy test
Women of childbearing potential (WOCBP) must have a negative pregnancy test performed prior to the start of study drug
Negative serum pregnancy test within 7 days prior to starting study treatment in premenopausal women and women less than (< 2) years after the onset of menopause
Women of childbearing potential must have a negative serum or urine pregnancy test within 3 days prior to the start of SL-701 treatment.
Women of childbearing potential must have a negative serum pregnancy test within 7 days of first dose of study treatment and agree to use effective contraception as defined in the protocol.
For women of childbearing potential, a negative serum or urine pregnancy test with sensitivity less than 50 mIU/m within 72 hours before the start of study medication
Women of childbearing potential must have a negative serum or urine pregnancy test at the Screening Visit and be non-lactating.
Women of childbearing potential must have a negative serum pregnancy test within 14 days of first dose of study treatment.
Women of childbearing potential must have a blood or urine pregnancy test performed a maximum of 7 days before start of study treatment, and a negative result must be documented before start of study treatment
Pregnant and/or breastfeeding women; women of childbearing potential must have a negative serum pregnancy test within 14 days of study entry
Negative pregnancy test for pre-menopausal women
Women of childbearing potential must have a negative serum pregnancy test at the screening visit.
Women of childbearing potential only: negative serum pregnancy test done =< 7 days prior to registration
Women of childbearing potential (WOCBP) who have a positive serum pregnancy test within 14 days of the first administration of oral dasatinib
Women of childbearing potential must have a negative urine pregnancy test performed within 7 days before start of study treatment
Negative results of serum pregnancy test for premenopausal women of reproductive capacity and for women < 12 months after entering menopause
Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to randomization and agree to use effective contraception, during the study, and for 30 days after the last dose of study treatment
For women of childbearing potential, the participant must have a negative pregnancy test at screening and must agree to employ 2 forms of adequate contraceptive measures
Negative serum or urine pregnancy test in women with childbearing potential (WOCBP) defined as not post-menopausal for 12 months or no previous surgical sterilization, within one week prior to initiation of treatment; WOCBP must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 12 weeks after the last dose of study drug to minimize the risk of pregnancy
Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy test within 10 to 14 days and again within 24 hours of starting study drug
Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
Women of childbearing potential must have a negative pregnancy test at baseline prior to receiving any study drug and must practice effective contraception while on study; (pregnant or lactating patients are excluded)
Negative serum pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
Negative (serum) pregnancy test done =< 7 days prior to registration, for women of childbearing potential only; NOTE: Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
Women of child producing potential must agree to use effective contraceptive methods prior to study entry, during study participation, and for at least 30 days after the last administration of study medication. A serum pregnancy test within 72 hours prior to the initiation of therapy will be required for women of childbearing potential.
Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug; post-menopausal women (defined as age >= 50 years and no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test
Women of childbearing potential must have a negative blood pregnancy test
Women of childbearing potential and men should practice effective methods of contraception. Women of childbearing potential should have a negative urine or serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin within 7 days prior to the start of PRI 724.
Women of childbearing potential must have a negative urine or serum pregnancy test within 14 days prior to administration of everolimus
Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
Women of childbearing potential must have a negative serum pregnancy test before study entry.
Negative serum or urine pregnancy test for women of childbearing potential only
Negative serum pregnancy test within 14 days before starting study treatment in women with childbearing potential
Negative pregnancy test for women of childbearing potential
Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment
Women of childbearing potential must have a negative pregnancy test to be eligible
Negative pregnancy test for women of childbearing potential
Pregnant or lactating women are not eligible; women of childbearing potential must have a negative serum pregnancy test completed within 7 days of study entry, and use an appropriate form of birth control throughout the trial period
Women of childbearing potential must have had a negative pregnancy test (urine or serum) ? 7 days prior to enrollment, and willingness to use an acceptable method of contraception during participation in the study and for 3 months after the last dose.
Women of childbearing potential must have a negative serum pregnancy test prior to azacitidine treatment
Not pregnant and not nursing\r\n* For women of childbearing potential only, a negative pregnancy test done =< 14 days prior to registration is required
Negative serum pregnancy test done =< 7 days prior to registration, for persons of childbearing potential only
Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
Women of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to registration
Pregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 7 days of study entry
Women of childbearing potential must have a negative serum or urine pregnancy test within 3 days prior to treatment
Patients of childbearing potential must have a negative pregnancy test prior to the study entry and be practicing an effective form of contraception; pregnant women are excluded from this study
Negative serum or urine pregnancy test within 72 hours prior to registration for women of childbearing potential and agrees to use contraception for the duration of the treatment cycle and for a minimum of 30-days following the end of therapy (a minimum estimate 95 days)
Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug; post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test
Negative pregnancy test done =< 14 days prior to registration, for women of childbearing potential only
Women of childbearing potential must have a negative pregnancy test performed within 7 days prior to the start of study drug
Negative serum pregnancy test within 7 days prior to commencement of dosing in women of childbearing potential
Negative serum pregnancy test done =< 7 days prior to registration only for women determined to be of childbearing potential by their treating physician
Not pregnant and not nursing; for women of childbearing potential only, a negative urine or serum pregnancy test done =< 14 days prior to registration and confirmation they are not nursing is required
Women of childbearing age must have a negative serum pregnancy test within 14 days prior to registration
Premenopausal women (including women who have had a tubal ligation and for women less than 12 months after the onset of menopause) must have a negative serum pregnancy test
Women of childbearing potential must have a negative pregnancy test and agree to practice a medically acceptable contraception regimen for the study duration. Women who are postmenopausal for at least 1 year (> 12 months since last menses) or are surgically sterilized do not require this test
Women of childbearing potential must have a negative urine pregnancy test at screening, and
Pregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 14 days of study entry
Non-pregnant; women of childbearing potential must have a negative pregnancy test to participate in this study
Pregnant females (women of childbearing potential must have a negative serum pregnancy test prior to enrollment)
Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
Negative serum pregnancy test within 2 weeks prior to registration for women of childbearing potential
Negative pregnancy test for women of childbearing potential
Negative serum pregnancy test (in women of childbearing potential) =< 14 days prior to Step 2; women of childbearing potential and men who are sexually active must practice adequate contraception while on study
All pre-menopausal women will require a urine qualitative pregnancy test to exclude pregnancy; pregnant women will be excluded from the study
Negative pregnancy test done =< 7 days prior to registration (for women of childbearing potential only)
Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug; post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test; the definition of adequate contraception will be based on the judgment of the investigator
Negative pregnancy test (serum or urine) done =< 7 days prior to registration, for women of childbearing potential only (determined per clinician discretion)
Not pregnant; for women of childbearing potential only, a negative pregnancy test done =< 28 days prior to registration is required
Women of childbearing potential : negative pregnancy test
Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of treatment.
Negative (serum or urine) pregnancy test, for women of childbearing potential only
Negative serum pregnancy test within 7 days prior to study treatment in premenopausal women and women less than or equal to (<=) 12 months post-menopause. Postmenopausal state is defined as amenorrhea for greater than (>) 12 months.
Negative serum pregnancy test within 2 weeks prior to registration for women of childbearing potential
Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
Negative urine or serum pregnancy test performed =< 7 days prior to registration, for women of childbearing potential only
Negative (serum) pregnancy test done =< 7 days prior to randomization, for women of childbearing potential only
Women of childbearing potential (women with regular menses, women with amenorrhea, women with irregular cycles, women using a contraceptive method that precludes withdrawal bleeding, and women who have had a tubal ligation) are required to have a negative urine pregnancy test within 14 days prior to the first dose of lithium
Negative pregnancy test done ? 7 days prior to registration, for women of childbearing potential
Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
Women who are able to become pregnant must have a confirmed negative pregnancy test result prior to enrollment; women >= 50 years of age who have not had a menstrual period in the past year; and women who have had a hysterectomy, both ovaries removed, or a tubal ligation; will not be required to have a pregnancy test
Women of childbearing potential (WCBP) must have a negative urine pregnancy test within 7 days prior to the first study intervention
Negative pregnancy test at time of signing consent for women of childbearing potential
Women of childbearing potential must have a negative urine or serum pregnancy test
Negative pregnancy test for women of childbearing potential
Women who are able to become pregnant must have a confirmed negative pregnancy test result prior to enrollment; women who are >= 60 years old or who have had a hysterectomy, both ovaries removed, or a tubal ligation will not be required to have a pregnancy test
Positive pregnancy test or breastfeeding of patient or donor (women of childbearing age only)
Positive pregnancy test (women of childbearing age only)
Positive pregnancy test or nursing (women of childbearing age only)
Women of childbearing age with a negative pregnancy test documented prior to enrollment
Not pregnant or nursing; note: a negative (serum or urine) pregnancy test must be documented =< 7 days prior to registration/randomization for women of childbearing potential
A negative serum pregnancy test within 7 days prior to the first dose of Study treatment in women of childbearing potential (ie, all women except those who are post menopause for ? 1 year or who have a history of hysterectomy or surgical sterilization)
Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to enrollment, must be non-lactating and must agree to use adequate contraception prior to enrollment and for the duration of study participation
Women of childbearing potential in whom the possibility of pregnancy cannot be excluded by a negative pregnancy test or who are lactating
Patients must not be pregnant or breast feeding; women of childbearing potential are required to obtain a negative pregnancy test within 14 days of starting treatment; effective contraception (men and women) must be used in subjects of childbearing potential
Women of childbearing potential must have a negative pregnancy test
Women of childbearing potential (WCBP): negative serum pregnancy test, obtained within 14 days prior to PET scan
Women who are pre-menopausal must have a negative serum pregnancy test
Negative pregnancy test within 7 days prior to starting the study in premenopausal women; women of non-childbearing potential may be included without pregnancy test if they are either surgically sterile or have been postmenopausal for >= 1 year
Women of reproductive potential must have a urine pregnancy test day of injection
Women of childbearing potential who refuse a pregnancy test
Pregnant or breast feeding women are excluded from this study; women of childbearing potential must have a negative pregnancy test within 3 days prior to receiving indocyanine green
Pregnant and/or breastfeeding; women of childbearing potential must have a negative urine or serum pregnancy test no more than 3 days prior to FDOPA injection
Negative serum pregnancy test in women of childbearing potential
Women who are pre-menopausal must have a negative serum pregnancy test
Women of childbearing age must have a negative blood pregnancy test
Women who are pre-menopausal must have a negative serum pregnancy test
Pregnant or lactating; women of childbearing potential with either a positive or no pregnancy test at baseline are excluded
Women of childbearing potential must have a negative serum or urine pregnancy test performed within 7 days prior to first PET/MRI
Pregnancy or breastfeeding; women of childbearing potential must have a negative pregnancy test prior to undergoing MRI/PET imaging; post-menopausal status may be established by patient reported history of absence of menses over the last 12 months
Women of childbearing potential who refuse a pregnancy test (performed during screening)
Women of childbearing potential (WOCBP) must have a negative pregnancy test (serum or urine) within the 7 days prior to study drug administration, and within the 3 days before the first study drug administration, or a negative pregnancy test within the 24 hours before the first study drug administration.
Women must have a negative serum pregnancy test within 7 days prior to the first dose of study drug or be surgically or biologically sterile or postmenopausal
Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to enrollment.
Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
Pregnant or breastfeeding (negative serum or urine pregnancy test required for women of childbearing potential), or unable to maintain use of contraception while on study and for 60 days after the last dose of avelumab
Women of childbearing potential will undergo a pregnancy test
Women of childbearing age must have a negative pregnancy test at screening/baseline
Women of childbearing potential will be required to have a urine pregnancy test
Women of childbearing potential must have a negative pregnancy test prior to the administration of protocol specified interventions
Negative urine pregnancy test for women of childbearing potential within 7 days of baseline [D10]phe dosing
Negative serum pregnancy test at screening for women of childbearing potential
Negative serum pregnancy test within 7 days prior to study treatment in premenopausal women and women <= 2 years after start of menopause
Pregnant or lactating women; all pre-menopausal women being screened must have a negative serum pregnancy test within 14 days prior to commencement of dosing; women of non-childbearing potential may be included if they are either surgically sterile or have been postmenopausal for >= 1 year
Women of childbearing age will have to undergo a pregnancy test that will be provided free of charge
Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test within 24 hours prior to the restart of study drug
Women of reproductive potential should have a negative serum or urine pregnancy test within one week prior to radiation planning CT scan
For women of childbearing potential, negative serum pregnancy test within 7 days of enrollment
Negative serum or urine pregnancy test must be obtained within 7 days prior to the first dose of study drug in women of childbearing potential. Negative results must be available prior to study drug administration. Pregnancy tests will be repeated regularly during treatment
Pregnant women. Women of reproductive potential must have a negative serum or urine pregnancy test performed within 7 day
